Physician profile
Walter M Klein
NPI 1326083833
$2,993.87
in general payments reported to CMS, 2019-2025
26 companies · $166 in 2025
The $166 reported for 2025 was more than what 77% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $398 · 2022: $118 · 2023: $787 · 2024: $617 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,570.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $577.00 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Lilly USA, LLC | $292.88 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $284.29 | 2019-2023 | Adcetris, Tukysa |
| Merck Sharp & Dohme LLC | $247.62 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Scientific Affairs, LLC | $237.76 | 2019-2020 | |
| Eisai INC. | $144.86 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $122.90 | 2020 | |
| Incyte Corporation | $122.28 | 2022-2024 | Jakafi, Monjuvi, Pemazyre |
| Alexion Pharmaceuticals, INC. | $120.82 | 2019 | |
| Mirati Therapeutics, INC. | $112.23 | 2023-2024 | Krazati |
| Shire North American Group INC | $101.93 | 2019 | |
| Janssen Biotech, INC. | $95.63 | 2020-2024 | Erleada, Rybrevant |
| Daiichi Sankyo INC. | $76.80 | 2024-2025 | Enhertu, Datroway |
| Roche Diagnostics Corporation | $75.82 | 2023 | |
| Genmab U.S., INC. | $71.82 | 2023-2024 | Tivdak, Epkinly |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $46.54 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $44.02 | 2019 | |
| Genentech USA, INC. | $42.07 | 2023-2024 | Tecentriq |
| Pfizer INC. | $37.77 | 2024 | |
| Morphosys, US INC. | $31.36 | 2023 | Monjuvi |
| Celgene Corporation | $25.71 | 2023 | Pomalyst |
| Novartis Pharmaceuticals Corporation | $24.10 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.63 | 2025 | Libtayo |
| Clovis Oncology, INC. | $15.55 | 2019 | |
| Taiho Oncology, INC. | $11.61 | 2019 | |
| Exelixis INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.